An Overview of Adaptimmune Therapeutics's Earnings

Adaptimmune Therapeutics ADAP is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Adaptimmune Therapeutics to report an earnings per share (EPS) of $-0.15.

Anticipation surrounds Adaptimmune Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Overview of Past Earnings

Last quarter the company beat EPS by $0.32, which was followed by a 3.67% drop in the share price the next day.

Performance of Adaptimmune Therapeutics Shares

Shares of Adaptimmune Therapeutics were trading at $0.8241 as of November 11. Over the last 52-week period, shares are up 60.22%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.